UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

FORM 10-Q

(Mark One)

[X]

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For Quarterly Period EndedSeptember 30, 20172021

or

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Forthe Transition period fromto ______________to ______________

Commission File Number:000-50099

Commission File Number: IMAGING3, INC.000-50099

GRAPEFRUIT USA, INC.

(Exact name of registrant as specified in its charter)

CALIFORNIAdelaware95-4451059
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)(I.R.S. Employer
Identification No.)

3022 North Hollywood Way, Burbank, California 915051000 Northwest Street, Mid-Town Brandy Wine, Suite 1200-3094, Wilmington, DE19801

(Address of principal executive offices) (Zip Code)

(818) 260-0930310-575-1175

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of exchange on which registered
No par value common stockGPFTOTCQB

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $0.0001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes[X]No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes[X]No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One).

Large accelerated filer[  ]Accelerated filer[  ]
Non-accelerated filer[  ]Smaller reporting company[X]
(Donot check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]No[X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

As of November 13, 2017,5, 2021, the number of shares outstanding of the registrant’s class of common stock was 310,082,295.554,162,744.

 

 

 

TABLE OF CONTENTS

Page
PART I.FINANCIAL INFORMATION
Item 1.Condensed Financial Statements (Unaudited)34
Condensed Consolidated Balance Sheets at September 30, 20172021 (Unaudited) and December 31, 20162020 (Audited)34
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 20172021 and 20162020 (Unaudited)45
Condensed Consolidated Statements of Cash Flows for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited)6
Condensed Consolidated Statement of Stockholders’ Deficit for the Nine Months Ended September 30, 20172021 and 20162020 (Unaudited)57
Notes to Condensed Consolidated Financial Statements (Unaudited)68
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations1621
Item 3.Quantitative and Qualitative Disclosures About Market Risk1925
Item 4.Controls and Procedures1926
PART II.OTHER INFORMATION
Item 1.Legal Proceedings26
Item 1A.Risk Factors2026
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds2026
Item 3.Defaults Upon Senior Securities2027
Item 4.Mine Safety Disclosures2027
Item 5.Other Information2027
Item 6.Exhibits2027
SIGNATURES2128

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, plans and objectives of management and markets for our common stock are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our most recent Annual Report on Form 10-K and any updates described in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K as may be amended, supplemented or superseded from time to time by other reports we file with the U.S. Securities and Exchange Commission (the “SEC”). You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the reports we file with the SEC, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors in our SEC reports could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements. 

3

PART I. FINANCIAL INFORMATION

Item1. CondensedItem 1. Financial Statements (Unaudited)

IMAGING3,GRAPEFRUIT USA, INC.

CONDENSEDCONSOLIDATED BALANCE SHEETS

AT SEPTEMBER 30, 2017 AND DECEMBER 31, 2016

  

September 30, 2021

  

December 31, 2020

 
  (Unaudited)  (Audited) 
ASSETS        
         
CURRENT ASSETS:        
Cash $37,317  $299,895 
Accounts receivable  285,622   39,408 
Inventory  410,681   502,115 
Licensee agreement  44,000   63,800 
Other  70,319   43,644 
Total current assets  847,939   948,862 
NON-CURRENT ASSETS:        
Property, plant and equipment, net  1,783,651   1,790,930 
Operating right of use - assets  62,942   131,786 
Investment in hemp  84,950   169,950 
Goodwill  250,000   - 
Other  7,459   7,459 
TOTAL ASSETS $3,036,941  $3,048,987 
         
LIABILITIES AND STOCKHOLDERS' DEFICIT        
         
CURRENT LIABILITIES        
Notes payable $256,634  $256,436 
Accrued loan interest  920,619   758,107 
Related party payable  420,872   488,433 
Legal settlements - current portion  75,572   180,740 
Subscription payable  251,141   791,992 
Derivative liability  27,431   118,641 
Capital lease - current portion  43,497   67,071 
Operating right of use - liability - current portion  65,486   82,038 
Convertible notes - current portion  1,907,021   829,072 
Accounts payable and accrued expenses  817,836   807,051 
Total current liabilities  4,786,109   4,379,581 
         
Legal settlements - long-term  -   29,226 
Capital lease  13,347   38,835 
Operating right of use - liability  -   52,724 
Long-term notes payable, net  907,762   904,633 
Long-term convertible notes, net of discount  1,547,066   2,323,735 
Total long-term liabilities  2,468,175   3,349,153 
         
TOTAL LIABILITIES  7,254,284   7,728,734 
         
STOCKHOLDERS’ DEFICIT        
Common stock ($0.0001 par value, 1,000,000,000 shares authorized; 554,162,744 and 505,700,437 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively)  55,416   50,570 
Preferred stock ($0.0001 par value, 1,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020)  -   - 
Additional paid in capital  10,801,207   6,591,177 
Accumulated deficit  (15,066,663)  (11,321,494) 
Total stockholders’ deficit  (4,210,040)  (4,679,747)
Noncontrolling interest  (7,303)  - 
Total deficit  (4,217,343)  (4,679,747)
TOTAL LIABILITIES AND STOCKHOLERS' DEFICIT $3,036,941  $3,048,987 

  September 30, 2017  December 31, 2016 
  (Unaudited)    
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents $26,079  $22,638 
         
Total current assets  26,079   22,638 
         
PROPERTY AND EQUIPMENT, net  -   - 
Total assets $26,079  $22,638 
         
LIABILITIES AND STOCKHOLDERS’ DEFICIT        
         
CURRENT LIABILITIES        
         
Accounts payable and accrued expenses $802,364  $1,825,080 
Convertible notes payable, net of discount of $220,748 and $115,822 respectively  1,278,232   771,028 
Derivative liability  110,506   5,532,898 
Deferred revenue  27,205   41,829 
Total current liabilities $2,218,307  $8,170,835 
LONG TERM LIABILITIES        
Administrative claims payable $1,026,809  $- 
         
TOTAL LIABILITIES $3,245,116  $8,170,835 
COMMITMENTS AND CONTINGENCIES, note 9  -   - 
         
STOCKHOLDERS’ DEFICIT        
Common stock and additional paid-in capital authorized 1,000,000,000 shares, no par value and 309,313,065 and 243,844,093 issued and outstanding as of September 30, 2017 and December 31, 2016 respectively.  9,417,055   7,829,273 
Accumulated deficit  (12,636,092)  (15,977,470)
Total stockholders’ deficit  (3,219,037)  (8,148,197)
Total liabilities and stockholders’ deficit $26,079  $22,638 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3,

4

GRAPEFRUIT USA, INC.

CONDENSEDCONSOLIDTED STATEMENTS OF OPERATIONS

(UNAUDITED)(Unaudited)

 Three months
ended
September 30,
2017
 Three months
ended
September 30,
2016
 Nine months
ended
September 30,
2017
 Nine months
ended
September 30,
2016
  Three months ended Three months ended Nine months ended Nine months ended 
          September 30, 2021 September 30, 2020 September 30, 2021 September 30, 2020 
Net revenues $4,946  $23,195  $14,624  $40,393 
                
Revenue $153,476  $1,306,201  $586,780  $2,580,412 
Cost of goods sold  221   1,905   14,263   10,247   346,073   1,123,717   926,671   2,385,804 
Gross profit  4,725   21,290   361   30,146 
                
Gross profit (loss)  (192,597)  182,484   (339,891)  194,608 
Operating expenses:                                
General and administrative expenses  652,178   417,845   1,507,048   2,051,898 
Sales  3,800   67,479   5,760   106,594 
Stock based compensation  25,980   -   265,024   - 
Stock option expense  32,877   -   65,754   - 
General and administrative  352,462   289,767   1,011,199   974,925 
Total operating expenses  652,178   417,845   1,507,048   2,051,898   415,119   357,246   1,347,737   1,081,519 
                                
Loss from operations  (647,453)  (396,555)  (1,506,687)  (2,021,752)  (607,716)  (174,762)  (1,687,628)  (886,911)
                
Other income (expense):                                
Interest expense  (120,691)  (764,619)  (542,047)  (2,723,355)  (388,273)  (532,410)  (1,258,650)  (1,343,224)
Change in value of derivative instruments  72,277   138,407   1,714,502   (1,626,839)  13,877   (7,014,164)  91,210   (7,946,046)
Gain on extinguishment of debt  -   -   3,668,776   - 
Other income  28,233   48,667   7,633   256,135 
Gain (loss) on extinguishment of debt  -   31,642   (398,373)  105,945 
Gain (loss) on extinguishment of debt - related parties  -   -   (491,998)  - 
Total other income (expense)  (20,181)  (577,545)  4,848,864   (4,094,059)  (374,396)  (7,514,932)  (2,057,811)  (9,183,325)
                                
Income (loss) before income taxes  (667,634)  (974,100)  3,342,177   (6,115,811)  (982,112)  (7,689,694)  (3,745,439)  (10,070,236)
                                
Provision for income taxes  -   -   800   800 
Tax provision  -   -   -   - 
                                
Net income (loss) $(667,634) $(974,100) $3,341,377  $(6,116,611)  (982,112)  (7,689,694)  (3,745,439)  (10,070,236)
                                
Net income (loss) per share - Basic $(0.00) $(0.01) $0.01  $(0.03)
Net income (loss) per share - Diluted $(0.00) $(0.01) $0.01  $(0.03)
Weighted average common stock outstanding - Basic  289,109,736   194,813,806   265,366,406   205,139,866 
Weighted average common stock outstanding - Diluted  289,109,736   194,813,806   286,364,229   205,139,866 
Loss attributable to noncontrolling interest  (270  -   (270)  - 
                
Net (loss) income attributable to Grapefruit USA, Inc. $(981,842) $(7,689,694) $(3,745,169) $(10,070,236)
                
Net loss per share - Basic and diluted $(0.00) $(0.02) $(0.01) $(0.02)
Weighted average common stock outstanding - Basic and diluted  550,277,467   499,182,611   515,339,023   495,837,104 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3,

5

GRAPEFRUIT USA, INC.

CONDENSEDCONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED

SEPTEMBER 30, 2017 AND 2016(Unaudited)

(UNAUDITED)

  Nine months ended  Nine months ended 
  September 30, 2021  September 30, 2020 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $(3,745,169) $(10,070,236)
Adjustments to reconcile net loss to net cash used for operating activities:        
Net loss attributable to non-controlling interest  (270)  - 
Depreciation and amortization expense  69,598   126,066 
Amortization of debt discount  692,129   - 
Change in value of derivative  (91,210)  7,946,046 
Stock-based compensation for services  265,024   244,167 
Stock option expense  65,754   - 
Loss on extinguishment of debt  

398,373

   

479,531

 
Non-cash interest  -   

(18,772

)
Loss on extinguishment of debt - related parties  

491,998

   - 
Changes in operation assets and liabilities:        
Accounts Receivables  (261,452)  - 
Inventory  91,434   (146,726)
Prepaid expense and current assets  (6,875)  - 
Investment in hemp  85,000   - 
Right-of-use assets  68,844   - 
Accounts payable  70,785  (29,189)
Other  -   (20,000)
Accrued expenses and other current liabilities  487,792   386,200 
Accrued loan interest expense  388,940   256,687 
Right-of-use liability  (69,276)  (64,109)
Net cash (used for)/provided by used for operating activities  (998,581)  (910,335)
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Net cash received from acquisition  69   - 
Purchase of land and equipment  (62,319)  (25,469)
Net cash used for investing activities  (62,250)  (25,469)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Principal repayment of capital lease liability  (49,062)  (40,803)
Repayment of legal liability  (16,393)  - 
Proceeds from convertible notes, net  450,000   707,500 
Proceeds from (repayment of) loans, net  -   168,343 
Repayment of loan principal  (4,772)  - 
Proceeds from related parties  93,080   - 
Contributions from non-controlling interest  400   - 
Proceeds from exercise of warrants  250,000   - 
Proceeds from sale of common stock  75,000   - 
Net cash proceeds from financing activities  798,253   835,040 
         
NET INCREASE (DECREASE) IN CASH  (262,578)  (100,764)
         
CASH, BEGINNING BALANCE  299,895   266,607 
         
CASH, ENDING BALANCE $37,317  $165,843 
         
SUPLEMENTAL DISCLOSURE ON CASH FINANCING ACTIVITY        
Cash paid for interest expense  87,883   110,340 
         
SUPLEMENTAL DISCLOSURE ON NON-CASH FINANCING ACTIVITY        
Shares issued for legal settlement  1,090,462   - 
Shares issued for conversion of notes payable  996,620   640,597 
Shares issued for debt settlement with related parties  699,236   - 
Shares issued for compensation  -   388,572 
Shares issued for settlement of debt  -   79,754 
Shares issued for acquisition  

250,000

   - 
Reclassification of derivative liabilities to APIC  -   

395,067

 

  Nine months ended  Nine months ended 
  September 30, 2017  September 30, 2016 
       
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss) $3,341,377  $(6,116,611)
Adjustments to reconcile net income (loss) to net cash used for operating activities:        
Non Cash Interest  427,097   2,675,797 
Stock based compensation  -   139,535 
(Gain) loss on extinguishment of debt  (3,668,776)  - 
Change in value of derivatives  (1,714,502)  1,626,839 
Shares issued for services  648,300   1,612,500 
Warrants issued for service  194,956   - 
(Increase) / decrease in current assets:        
Accounts receivable  -   51,505 
Increase / (decrease) in current liabilities:        
Accounts payable and accrued expenses  207,578   (345,869)
Deferred revenue  (14,624)  (38,393)
Net cash used for operating activities  (578,594)  (394,697)
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from issuance of notes payable  575,035   295,000 
Proceeds from sale of stock, net of offering costs  7,000   159,900 
Net cash provided from financing activities  582,035   454,900 
         
NET INCREASE IN CASH & CASH EQUIVALENTS  3,441   60,203 
         
CASH & CASH EQUIVALENTS, BEGINNING BALANCE  22,638   9,508 
CASH & CASH EQUIVALENTS, ENDING BALANCE $26,079  $69,711 
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITY        
Notes and accrued interest converted to common stock $196,797  $- 
Promissory notes issued for no cash consideration $151,222  $- 
Compensation paid through exercise of options $200,000  $- 

The accompanying notes formare an integral part of these unaudited condensed consolidated financial statements

IMAGING3, INC.

Notes to Condensed Financial Statements

(Unaudited)

6

 

1.

GRAPEFRUIT USA, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)

                                       
  Deficit Attributable to Grapefruit USA, Inc.       
                      
  Common Stock  Additional     Total  Non-    
  Number of     Paid in  Accumulated  Stockholders'  controlling  Total 
  Shares  Amount  Capital  Deficit  Deficit  Interest  Deficit 
                      
Balance as of December 31, 2019  486,320,329  $48,632  $2,781,839  $(7,264,498) $(4,434,027) $-  $(4,434,027)
                                       
Shares issued for services  900,000   90   318,240   -   318,330   -   318,330 
                             
Shares issued for settlement  7,213,933   721   565,572   -   566,293   -   566,293 
                             
Shares issued with debt  915,795   92   44,782   -   44,874   -   44,874 
Shares issued upon warrant exercise                            
Shares issued upon warrant exercise, shares                            
                             
Shares issued for note conversion  9,100,380   910   79,844   -   80,754   -   80,754 
Shares issued for related party debt                            
Shares issued for related party debt, shares                            
Stock options granted pursuant to board of director agreement                            
Shares issued for purchase of stock                            
Shares issued for purchase of stock, shares                            
Shares issued for acquisition                            
Shares issued for acquisition, shares                            
Equity investment                            
Reclassification from derivative liability  -   -   395,067   -   395,067   -   395,067 
Noncontrolling interest Summit Boys                            
Net loss  -   -   -   (10,070,236)  (10,070,236)  -   (10,070,236)
                             
Balance as of September 30, 2020  504,450,437  $50,445  $4,185,344  $(17,334,734) $(13,098,945) $-  $(13,098,945)
                             
Balance as of December 31, 2020  505,700,437  $50,570  $6,591,177  $(11,321,494) $(4,679,747) $-  $(4,679,747)
                             
Shares issued for services  7,449,937   745   302,799   -   303,544   -   303,544 
                             
Shares issued for settlement  8,404,186   840   1,089,620   -   1,090,460   -   1,090,460 
                             
Shares issued upon warrant exercise  2,000,000   200   249,800   -   250,000   -   250,000 
                             
Shares issued for note conversion  13,352,264   1,335   995,285   -   996,620   -   996,620 
                             
Shares issued for related party debt  11,710,465   1,171   1,190,063   -   1,191,234   -   1,191,234 
                             
Stock options granted pursuant to board of director agreement  -   -   65,754   -   65,754   -   65,754 
                             
Shares issued for purchase of stock  1,000,000   100   74,900   -   75,000   -   75,000 
                             
Shares issued for acquisition  4,545,455   455   249,545   -   250,000   -   250,000 
                             
Equity investment  -   -   (7,736)  -   (7,736)  (7,033)  (14,769)
                             
Net loss  -   -   -   (3,745,169)  (3,745,169)  (270)   (3,745,439)
                             
Balance as of September 30, 2021  554,162,744  $55,416  $10,801,207  $(15,066,663) $(4,210,040) $(7,303) $(4,217,343)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

7

GRAPEFRUIT USA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

NOTE 1 – ORGANIZATION AND DESCRIPTIONNATURE OF BUSINESSOPERATIONS

Imaging3, Inc. (the “Company”Grapefruit USA, Inc (“we”, “our”, “us”, “we”“GBI”, “Imaging3”“Grapefruit”, or “the Company”) iswas formed as a California corporation incorporated on October 29, 1993 as Imaging Services, Inc. The Company filed a certificateAugust 28, 2017 and began operating in September 2017.

On July 10, 2019, Grapefruit closed the Share Exchange after the completion of amendment of articles of incorporation to change its name toall conditions subsequent contemplated by the Share Exchange Agreement among the parties thereto ( “SEA”), by which Imaging3, Inc. (“IGNG”) was acquired in a reverse acquisition (the “Acquisition”) by the former shareholders of Grapefruit, the accounting acquirer. Under the terms of the SEA executed on August 20, 2002.May 31, 2019, IGNG became obligated to issue to Grapefruit’s existing shareholders that number of newly issued restricted IGNG common shares such that the former Grapefruit shareholders (now new IGNG shareholders) will own approximately 81% of the post-Acquisition IGNG common shares and the current IGNG shareholders will retain 19% of the post-Acquisition IGNG common shares. At the time of the execution of the SEA, IGNG had approximately 85,218,249 outstanding shares of common stock. Therefore, IGNG issued to Grapefruit’s shareholders 362,979,114 IGNG common shares to Grapefruit’s current shareholder on a pro rata basis with their then-current ownership of Grapefruit of which Bradley Yourist and Daniel J. Yourist own a combined 72.26%, or approximately 259,967,136 shares. Accordingly, the financial statements are prepared using the acquisition method of accounting with GBI as the accounting acquirer and IGNG treated as the legal acquirer and accounting acquiree. Because Imaging3, Inc. did not meet the accounting definition of an operating business, having only nominal assets, the reverse merger transaction was treated as a recapitalization and no goodwill was recognized.

The Company’s primary business is refurbishment and sale of medical equipment, parts and services to hospitals, surgery centers, research labs, physician offices and veterinarians. Equipment sales include new c-arms, c-arms tables, remanufactured c-arms, used c-arm and surgical tables. Part sales comprise new or renewed replacement parts for c-arms.

The Company has developedapplied for and received our provisional distribution renewal licensure which allows us to operate through June 14, 2022. Our annual manufacturing license has been renewed by the California Department of Health. Grapefruit has not yet applied for a proprietary medical technology designedlicense to produce 3D medical diagnostic imagescultivate and will not until construction has begun on our cultivation facility. We own two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park. The location within Coachillin’ allows the Company to apply for and hold every cannabis license available under the California Cannabis laws.

We intend to buildout out the real time. property into a distribution, manufacturing and high-tech cultivation facility to facilitate our goal to become a seed to sale, fully vertically integrated Cannabis and CBD product Company. Grapefruit’s plans include an indoor 22,000 square foot multi-tiered canopy and adjoining tissue culture rooms.

We believe Imaging3 technology hasbecame members of the potential to contribute toIndian Canyon and 18th Property Association on September 19, 2017 and have an ownership interest of 1.46% based upon the improvement77,156 gross parcel square foot of healthcare. Our technology is designed to cause 3D imagesour property located in an approximately 5.3 million square foot facility. As of September 30, 2021, the common areas continue to be instantly constructed using high-resolution fluoroscopy. These images can be used as real time references for any current or new medical procedures in which multiple frames of referencebuilt throughout the entire canna-business park and are required to perform medical procedures on or in the human body. This technology is still in development and the Company intends to seek approval from the Food and Drug Administration (“FDA”), which will allow us to offer our product to healthcare providers.not complete.

2. NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BasisThe accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”).

The unaudited financial statements as of Presentation

On September 13, 2012 (the “Petition Date”),30, 2021 and December 31, 2020, and for the Company filed a voluntary petitionnine months ended September 30, 2021 and September 30, 2020, have been prepared in accordance with the federal bankruptcy courtaccounting principles generally accepted in Los Angeles, California, to enter bankruptcy under Chapter 11 of the United States Bankruptcy Code. On or about July 15, 2013, our Plan of Reorganization was approved by the United States Bankruptcy Court. On July 30, 2013, we emerged from bankruptcy and continued operations under the terms and conditions of our Bankruptcy Reorganization Plan as it applies to post bankruptcy operations. For accounting purposes, management deemed the effective date of the Chapter 11 Plan (the “Plan”) to be June 30, 2013. The Company’s operations between July 1, 2013 and July 30, 2013 were not significant. The Plan adopted by Imaging3, Inc. is a reorganizing plan. Payments under the Plan were made by utilizing existing cash on hand, borrowings on a secured and unsecured basis, future cash flow, if any, capital raised through the sale of our common stock in private placements, and by conversion of debt to equity.

Upon emergence from bankruptcy, Imaging3 adopted fresh-start accounting which resulted in Imaging3 becoming a new entity for financial reporting purposes. Imaging3 applied fresh start accounting as of July 1, 2013. As a result of the application of fresh start accounting and the effects of the implementation of the plan of reorganization, the financial statements on or after July 1, 2013 are not comparable with the financial statements prior to that date.

The accompanying unaudited interim financial statements havebeenpreparedinaccordance with the rules and regulations of the Securities and Exchange Commissionforthe presentation of interim financial information buton the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. They do not include all of the information and footnotes required by generally accepted accounting principlesGAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessaryfora fair presentation have been included. Itissuggested thatTherefore, these condensed financial statements should be readinconjunction with the Company’s audited financial statements and notes thereto included infiled with the Company’s annual report on Form 10-KSEC for the fiscal year ended December 31, 2016. The2020.

Basis of ConsolidationSubsidiaries are entities controlled by the Company. Control exists when the Company followseither has a controlling voting interest or is the same accounting policiesinpreparation of interim reports. Results of operationsforthe interim periods are not indicative of annual results.

Going Concern

The Company’s financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has historically incurred net losses. The continuing losses have adversely affected the liquidity of the Company.

In view of the matters described in the preceding paragraph, recoverabilityprimary beneficiary of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and to succeed in its future operations.variable interest entity. The financial statements do not include any adjustments relating toof subsidiaries are included in the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary as a result of the Company’s going concern uncertainty. Management believes there is substantial doubt about the Company’s ability to continue as a going concern.

Management’s plan regarding this matter is to, amongst other things, seek additional debt or equity financing, increase our sales volume, and continue seeking approvalconsolidated financial statements from the FDA to bringtomarket our smart scan technology imaging platform. We cannot assure youdate that funds from these sources will be available when needed or, if available, will be on terms favorabletous ortoour stockholders.Ifwe raise additional funds or settle liabilities by issuing equity securities,control commences until the percentagedate that control ceases.

In August 2021, the Company entered into a Stock Purchase Agreement acquiring the majority ownership and control of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to thoseSummit Boys, Inc., a very well-known and established cannabis extraction brand with product lines in retail stores throughout the State of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affectedifweare unable to raise additional capital or operate profitably.

California. The Company anticipates that further equity/debt financings will be necessary to continue to fund operationsplans on continuing the business without interruption and plans on licensing the Summit Boys brand in the futureState of Oklahoma under that State’s newly enacted legalized statutory scheme for cannabis products. This non-significant and there is no guarantee that such financings will be available or,non-operating subsidiary has been consolidated with Grapefruit’s financial statements. As consideration, the Company issued 4,545,455 shares of common stock for 51% ownership if available, on acceptable terms.Summit Boys, Inc.

A summary of the Company’s significant accounting policies consistently applied in the preparation of the accompanying financial statements follows:

Use of Estimates

In preparing – The preparation of our financial statements in conformity with accounting principles generally acceptedinthe United States of America, management is requiredU.S. GAAP requires us tomake estimates, assumptions and assumptionsjudgments that affect the reported amounts of assetsandliabilities and the disclosure of contingent assetsandliabilities atas of the date of theour financial statements and the reported amounts of revenues and expenses during the reporting period.Actualperiods presented.

8

We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from those estimates.these estimates, making it possible that a change in these estimates could occur in the near term. The company’s most significant estimates related to useful life for depreciation, the value of long-lived assets and related impairment, and provision for income taxes of property and equipment.

CashInventory– Inventory is comprised of raw material, work in process and Cash Equivalents

finished goods. The Company considers all liquid investments with a maturityfollowing sets forth selected items from our inventory as of three months or less from the date of purchase that are readily convertible into cash to be cash equivalents. The Company maintains its cash in bank deposit accounts that may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company had no cash equivalents at September 30, 2017.2021 and December 31, 2020:

SUMMARY OF INVENTORY

  September 30, 2021  December 31, 2020 
Raw material $56,299  $16,892 
Work in process  -   23,566 
Finished goods  354,382   461,657 
Total inventory $410,681  $502,115 

Revenue Recognition

Revenueisrecognized upon shipment, provided that evidenceWe periodically review the value of an arrangement exists, titleour inventory and riskprovide a write-down of loss have passedtothe customer, fees are fixed or determinable and collectioninventory based on our assessment of the related receivablemarket conditions. Any write-down is reasonably assured. Revenueisrecorded net of estimated product returns, which isbasedupon the Company’s return policy, sales agreements, management estimates of potential future product returns relatedtocurrent period revenue, current economic trends, changesincustomer composition and historical experience. The Company accrues for warranty costs, sales returns, and other allowances based onitsexperience. Generally, the Company extends credit to its customers and does not require collateral.TheCompany performs ongoing credit evaluations of its customersandhistoric credit losses have been within management’s expectations and has a revenue receivables policy for serviceandwarranty contracts. Equipment sales usually have a one-year warranty of parts and service. After a one-year period, the Company contacts the buyertoinitiate the sale of a new warranty contractforone year. Warranty revenues are deferred and recognized on a straight line basis over the term of the contract or as services are performed.

Deferred Revenue

Deferred revenue consists substantially of amounts received from customers in advance of the Company’s performance service period. Deferred revenue is recognized as revenue on a systematic basis that is proportionate to the period that the underlying services are rendered, which in certain arrangements is straight-line over the remaining contractual term or estimated customer life of an agreement.

Accounts Receivable

The Company’s customer base is geographically dispersed. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded primarily on a specific identification basis.

Property & Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to expenses as incurredcost of goods sold.

Property, Plant and additions, renewals and betterments are capitalized. WhenEquipment, net– Our property and equipment are retired or otherwise disposedrecorded at cost. Assets held under capital leases are capitalized at the commencement of the relatedlease at the lower of the present value of minimum lease payments at the inception of the lease or fair value. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over estimated useful lives of four to seven years, and amortization is computed using the straight-line method over the life of the applicable lease. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the respectiveour accounts and any resulting gain or loss is includedreflected in operations. Depreciationour consolidated statements of operations.

Land Improvements – Our land improvements are recorded at cost provided by our property and equipment is provided usingassociation. These costs will continue to be capitalized until construction has been completed. Land improvements will not be depreciated after the straight-line method for all assets with estimated lives of three to eight years.construction has been completed by the property association.

Impairment of Long-Lived Assets

Long-lived Impairment Assessment – Our long-lived assets are reviewed forsubject to an impairment whenever events or changes in circumstances indicatetest if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying amountvalue of an assetintangibles or other long-lived assets may not be recoverable throughbased upon the estimatedexistence of one or more indicators of impairment, we use the projected undiscounted cash flows expectedflow method or realizable value to resultdetermine whether an impairment exists, and then measure the impairment using discounted cash flows.

Revenue Recognition– The Company derives revenues from the use and eventual dispositionsale of product in accordance to ASC Topic 606. Revenues are recognized when control of the assets. Whenever any such impairment exists, an impairment loss will be recognized for the amount by which the carrying value exceeds the fair value.

The Company tests long-lived assets, including property, plant, equipment and intangible assets subject to periodic amortization, for recoverability at least annuallypromised goods or more frequently upon the occurrence of an event or when circumstances indicate that the net carrying amountservices is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. The Company considers historical performance and future estimated results in its evaluation of potential impairment, and then compares the carrying amount of the assettransferred to the future estimated cash flows expected to result fromcustomer in an amount that reflects the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows,consideration the Company measures the amount of impairment by comparing the carrying amount of the assetexpects to its fair value. The estimation of fair valuebe entitled to in exchange for transferring those goods or services.

Revenue is generally measured by discounting expected future cash flows at the rate the Company utilizes to evaluate potential investments. The Company estimates fair valuerecognized based on the information availablefollowing five step model:

-Identification of the contract with a customer
-Identification of the performance obligations in the contract
-Determination of the transaction price
-Allocation of the transaction price to the performance obligations in the contract
-Recognition of revenue when, or as, the Company satisfies a performance obligation

9

Performance Obligations

Sales of products are recognized when all the following criteria are satisfied: (i) a contract with an end user exists which has commercial substance; (ii) it is probable the Company will collect the amount charged to the end user; and (iii) the Company has completed its performance obligation whereby the end user has obtained control of the product. A contract with commercial substance exists once the Company receives and accepts a purchase order or once it enters into a contract with an end user. If collectability is not probable, the sale is deferred and not recognized until collection is probable or payment is received. Control of products typically transfers when title and risk of ownership of the product has transferred to the customer. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in making whatever estimates, judgmentsan amount based on the estimated relative standalone selling prices of the promised goods or services underlying each performance obligation. The Company uses an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus margin approach when one is not available. Historically the Company’s contracts have not had multiple performance obligations. The large majority of the Company’s performance obligations are recognized at a point in time related to the sale of products.

Cost of Goods Sold– Our cost of goods sold includes the costs directly attributable to revenue recognized and projections are considered necessary.includes expenses related to the production, packaging and labelling of cannabis products; personnel-related costs, fees for third-party services, such as testing and transportation costs related to our distribution services.

Basic and Diluted Net Income Per Share

Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share is basedonthe assumptionassumes that all dilutive convertible shares and stock options were converted or exercised. Dilutioniscomputed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (oratthetime of issuance,iflater), and asiffunds obtained thereby were usedtopurchase common stock at the average market price during the period. During 2016,2019, potentially dilutive securities were excluded from the computation of weighted average shares outstanding-diluted because their effect was anti-dilutive.

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

 September 30, 2021 December 31, 2020 
Numerator:           
Net income attributable to common shareholders, for the nine months ended September 30, 2017 $3,341,377 
    
Net income attributable to common shareholders $(3,745,169)  (4,229,851)
Denominator:            
Weighted-average number of common shares outstanding during the period  265,366,406   515,339,023   498,230,051 
Dilutive effect of stock options, warrants, and convertible promissory notes  20,997,823   -   - 
Common stock and common stock equivalents used for diluted earnings per share  286,364,229  $(0.01) $(0.00)

Derivative Financial Instruments

- The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financingtofund its business needs, including convertible notes and warrants and other instruments not indexedtoour stock. The Companyisrequiredtorecord its derivative instruments at their fair value. Changesinthe fair value of derivatives are recognizedinearnings in accordance with ASC 815. The Company’s only asset or liability measuredatfair value on a recurring basisisits derivative liability associated with warrants to purchase common stock and convertible notes.

Fair Value of Financial Instruments

The– We value our financial assets and liabilities using fair value accounting standard createsmeasurements. Fair value is based on the price that would be received to sell an asset or paid to transfer a three-level hierarchy to prioritizeliability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether the inputs usedare observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation techniqueshierarchy is based on the lowest level of input that is significant to derive fair values. The basis forthe fair value measurements for each level within themeasurement. The hierarchy is described below withprioritized into three levels (with Level 3 being the lowest) defined as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.

10

Level 2: Observable inputs other than prices included in Level 1, havingsuch as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated with observable market data.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the highest priorityfair value of the assets and liabilities. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.

The carrying amount of our cash and cash equivalents approximates fair value because of the short-term nature of the instruments. The carrying amount of our notes payable at December 31, 2019, approximates their fair values based on comparable borrowing rates available to the company. The Company evaluated the fair market value of LVCA using Level 3 inputs. From that measurement, the Company recorded an impairment of LVCA.

There have been no changes in Level 1, Level 2, and Level 3 having the lowest.

Level 1: Observable prices in active markets for identical assets or liabilities.
Level 2: Observable prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in the market.
Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable. These unobservable assumptions reflect estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of option pricing models, discounted cash flow models, and similar techniques.

The Company had the followingcategorizations and no changes in valuation techniques for these assets or liabilities for the nine months ended September 30, 2021 and year ended December 31, 2020.

SUMMARY OF DERIVATIVE LIABILITIES

  Level 1  Level 2  Level 3  Total 
Derivative Liabilities September 30, 2021 $-  $-  $27,431  $27,431 
Derivative Liabilities December 31, 2020 $-  $-  $118,641  $118,641 

Items measured at fair value on a recurringnon-recurring basis at September 30, 2017.

  Level 1  Level 2  Level 3  Total 
Derivative Liabilities $-  $-  $110,506  $110,506 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740-10, “Income Taxes” which requires the recognitionCompany’s prepaids and other current assets, long lived assets, including property and equipment, and goodwill are measured at fair value when there is an indicator of deferredimpairment and are recorded at fair value only when an impairment charge is recognized.

Income Taxes – Income tax assets and liabilities forare recorded using the expected futureasset and liability method. Under the asset and liability method, tax consequences of events that have been included in the financial statements or tax returns.

Under this method, deferred income taxesassets and liabilities are recognized for the tax consequences in future years ofattributable to differences between thefinancial statement carrying amounts of existing assets and liabilities and their respective tax bases of assetsas well as net operating loss andliabilitiesandtheir financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expectedtoaffect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assetstothe amount expectedtobe realized. The provision for income taxes represents the tax payableforthe period and the change during the period in deferredcredit carryovers. Future tax assets and liabilities.

Inventory

Inventory is stated at the lower of cost or net realizable value with cost determinedliabilities are measured using the first-in, first-out method.

Researchenacted tax rates expected to apply when the asset is realized, or the liability settled. The effect on future tax assets and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurredliabilities of a change in accordance with FASB ASC 730-10. Includedtax rates is recognized in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

Recent Accounting Pronouncements

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09,Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 is effective for annual and interim periods beginning after December 15, 2017. Early adoption is not permitted. The revenue recognition standard is required to be applied retrospectively, including any combination of practical expedients as allowedincome in the standard. We are evaluatingperiod that enactment occurs. To the impact, if any, of the adoption of ASU 2014-09 to our financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issuedASU2014-15,Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.ASU2014-15 changes to the disclosure of uncertainties about an entity’s abilitytocontinue as a going concern. These changes require an entity’s managementtoevaluate whether there are conditions or events, consideredinthe aggregate,extent that raise substantial doubt about the entity’s abilitytocontinue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be madeinthe financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or eventsinrelation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intendedtoat least mitigate the conditions or events that raise substantial doubt, and (iv)ifthe latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s abilitytocontinue as a going concern. These changes became effective for the Company for the 2017 annual period. The adoption of these changes did nothavea material impact on the financial statements.

In February 2016, the FASB issued ASU 2016-02,Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, the FASB issuedASU2016-09,ImprovementstoEmployee Share-Based Payment Accounting. ThisASUaffects entities that issue share-based payment awards to their employees. TheASUis designed to simplify several aspects of accounting for share-based payment award transactions which include – the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows and forfeiture rate calculations.ASU2016-09 will become effective for the Companyinthe first quarter of fiscal 2018. Early adoptionispermittedinany interim or annual period. The Companyiscurrently evaluating the impact of this guidance on its consolidated financial statements.

In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606), which amends certain aspects of the Board’s new revenue standard, ASU 2014-09, Revenue from Contracts with Customers. The standard should be adopted concurrently with adoption of ASU 2014-09 which is effective for annual and interim periods beginning after December 15, 2017. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part II of this updatewe do not have an accounting effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company is currently assessing the potential impact of adopting ASU 2017-11 on its financial statements and related disclosures.

3. ACCRUED EXPENSES

During 2003, the Company paid payroll net of taxesandaccrued said taxes without payment due to cash flow limitations resultingfroma2002warehouse fire that incinerated our inventory. The Company subsequently received a tax lien in 2005 related to 2003 payroll taxes from the Internal Revenue Serviceandcontinued to accrue interestandpenalty charges. The original amount was $104,052. In 2008, payments were made and the Internal Revenue Service issued a tax lien release for this amount and the liability carried on the Company’s books was relieved. In 2009, the Company was notified by the Internal Revenue Service that additional payroll taxes, interest, and penalty charges were still owed. After researching,consider it is believed that the Internal Revenue Service double booked the original payments made and releasedthelieninerror. Settlement was reached and the Companyiscurrently paying $2,578 per month on a total liability of $24,474 as of September 30, 2017, including interest. The Company recognized a reduction of accrued liability of approximately $200,000 relating to the settlement with the Internal Revenue Service, which was recorded as other income in 2016. This agreement will cure any default of the Company’s plan payments. The final payment is due on April 16, 2018.

4. INCOME TAXES

The Company’s book lossesandother timing differences resultina net deferred income tax benefit which is offset by a valuation allowance for anetdeferred asset of zero. The Company has concluded,inaccordance with the applicable accounting standards, thatit ismore likely than not that the Company may not realize the benefit of all of its deferreda future tax assets. Accordingly, management has providedasset will be recovered, we will provide a 100% valuation allowance against its deferredthe excess.

We follow the provisions of ASC 740, Income Taxes. Because of ASC 740, we make a comprehensive review of our portfolio of tax assets untilsuchtime as management believes thatitsprojections of future profits aswellas expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differencesinfuture results from our estimates could resultinmaterial differencesinthe realization of these assets. The Company has recorded a full valuation allowance related toallof its deferred tax assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax assetpositions in accordance with FASBrecognition standards established by ASC 740-10, “Accounting for Income Taxes.” This assessment included740.

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the evaluation of scheduled reversals of deferred tax liabilities,taxing authorities, while others are subject to uncertainty about the availability of carry forwardsandestimates of projected future taxable income. The availabilitymerits of the Company’s net operating loss carry forwards is subjecttolimitationifthereisa 50%position taken or more changeinthe ownershipamount of the Company’s stock.position that would be ultimately sustained. The provision for income taxes consists of the state minimum tax imposed on corporations of $800. The Company has adopted guidance issued by the FASB that clarifies the accountingforuncertainty in income taxes recognized inanenterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement processforfinancial statement recognition and measurementbenefit of a tax position taken or expected to be takenis recognized ina tax return. In making this assessment, a company must determine whether our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that a taxthe position will be sustained upon examination, based solely onincluding the technical meritsresolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the position and must assumebenefits associated with tax positions taken that exceeds the tax position will be examinedbytaxing authorities.TheCompany’s policyamount measured as described above istoinclude interestandpenalties relatedto reflected as a liability for unrecognized tax benefits in incomethe accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

We have created our tax expense.provision leveraging known tax court cases involving various marijuana dispensaries and other cannabis related businesses, including the section of the IRS Tax code of 280E. The Company hasU.S. Tax Code Section 280E is the federal statute that states that a business engaging in the trafficking of a Schedule I or II controlled substance, which includes cannabis and cannabis related products, are barred from taking the tax deductions or credits in their federal tax returns which are not recognized anyconsidered as part of the business’ cost of goods sold. Given the guidance offered by the Tax code 280E we have prepared our tax provision according to this tax code.

Interest and penalties associated with unrecognized tax benefits, anddoesnothaveif any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.

11

On December 22, 2017, the U.S. Tax Cuts and Jobs Act was enacted. U.S. tax reform introduced many changes, including lowering the U.S. corporate tax rate to 21 percent, changes in incentives, provisions to prevent U.S. base erosion and significant changes in the taxation of international income, including provisions which allow for the repatriation of foreign earnings without U.S. tax. The enactment of U.S. tax reform had no significant impact on our income taxes for the nine months ended September 30, 2021 and 2020, respectively.

Research and Development Expenses– Research and development (“R&D”) costs are charged to expense as incurred. Our R&D expenses include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.

General and Administrative Expenses– General and administrative expenses consist primarily of personnel-related costs, fees for professional and consulting services, travel costs, rent, bad debt expense, general corporate costs, and other costs of administration such as human resources, finance and administrative roles.

Commitments and Contingencies – Certain conditions may exist as of the date our financial statements are issued, which may result in a loss, but which will only be resolved when one or penaltiesmore future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies relatedtouncertain tax positions legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, the estimated liability would be accrued in our consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.

Net Loss Per Share – We compute net loss per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net loss per share includes no dilution and is computed by dividing the net loss available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share takes into consideration shares of common stock outstanding (computed under basic net loss per share) and potentially dilutive securities that are not anti-dilutive.

Cash and Cash Equivalents– The Company considers all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash equivalents may be invested in money market funds, certificates of deposit or other interest-bearing accounts.

Concentration of Credit Risk – Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.

Accounts Receivable and RevenueThe accounts receivable balance was $285,622as of September 30, 2017.2021 and $39,480 as of December 31, 2020. As the September 30, 2021, 61% of accounts receivable was split between two customers. In 2020, 99% of accounts receivable consisted of one customer. During the nine months ended September 30, 2021, we continue to diversify our customer base, and no more than 17% of the revenues with any one customer.For the nine months ended September 30, 2020, 60% of the net revenues generated with two customers.

Recently Issued Accounting Pronouncements – From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update (“ASU”). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our condensed consolidated financial statements upon adoption.

12

 

5.

Recently Issued Accounting Pronouncements Not Yet Adopted

Convertible Debt, and Derivatives and Hedging In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to improve financial reporting associated with accounting for convertible instruments and contracts in an entity’s own equity. ASU 2020-06 will be effective for the Company in the first quarter of 2022. The Company is currently evaluating the amended guidance and the impact on its consolidated financial statements and related disclosures.

Recently Issued Accounting Pronouncements Adopted

Accounting for Income Taxes In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic 740). The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for the Company in the first quarter of fiscal year 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

Equity Securities, Equity-method Investments and Certain Derivatives In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. The guidance provides clarification of the interaction of rules for equity securities, the equity method of accounting and forward contracts and purchase options on certain types of securities. ASU 2020-01 became effective for the Company in the first quarter of 2021. The adoption of this standard did not have any impact on the Company’s condensed consolidated financial statements.

NOTE 3 – GOING CONCERN

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the nine months ended September 30, 2021, we incurred a net loss of $3,745,169, had a working capital deficit of $3,938,170 and had an accumulated deficit of $15,066,663 at September 30, 2021. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no assurance that these events will be satisfactorily completed. As a result, there is doubt about our ability to continue as a going concern for one year from the issuance date of these financial statements

Management’s plan regarding this matter is to, amongst other things, seek additional equity financing by selling our equity securities and obtaining funds through the issuance of debt. We cannot be certain that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders may be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences and/or privileges senior to those of the holders of our common stock. Our ability to execute our business plan and continue as a going concern may be adversely affected if we are unable to raise additional capital or operate profitably.

On May 31, 2019, the Company executed the Stock Purchase Agreement (“SPA”) with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a registration rights agreement with Auctus (the “Registration Rights Agreement”) whereby we are obligated to file a registration statement to register the resale of the shares underlying the Securities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement . Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the SPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the day IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of $1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing were completed. The Company has received gross proceeds of $4,052,750.

13

In the first quarter of 2021, Auctus exercised 2,000,000 warrants at $0.125, for proceeds to the Company of $250,000 and issued a $450,000 convertible note to Auctus. During the second quarter of 2021, the Company sold 1,000,000 shares at $0.075.

NOTE 4 – RIGHT OF USE ASSET AND LIABILITY

We lease capital equipment in a suitable, compliant cannabis facility located in the city of Desert Hot Springs. In addition, we entered into this operating land lease agreement with Coachillin’ Holdings LLC on September 1, 2018 to rent approximately 2,268 square feet of leasable land area. The operating lease renews annually and has a base rent of $0.50 square foot of leasable area of the designated premise assigned by Coachillin’ Holdings LLC. We paid an initial non-refundable prepaid rent of $3,402 which was expensed during the three months following the signed agreement, and we will continue to pay $1,134 monthly.

The Company entered into a 36-month lease agreement for office space in July 2019 at $6,963 a month, with an approximate 2% increase annually.

The Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental borrowing rate of 6% to estimate the present value of the right of use liability.

The Company has right-of-use assets of $62,942, right-of-use liability of $65,486 as of September 30, 2021. Operating lease expense for the nine months ended September 30, 31, 2021 was $73,662.

The following table provides the maturities of lease liabilities at September 30, 2021:

SCHEDULE OF MATURITIES OF LEASE LIABILITIES

Maturity of Lease Liabilities   
2021  22,378 
2022  44,756 
2023  - 
2024  -��
2025    
2026 and thereafter  - 
Total future undiscounted lease payments  67,134 
Less: Interest  (1,648)
Present value of lease liabilities $65,486 

NOTE 5 – INVENTORY

At September 30, 2021 and December 31, 2020, our inventory was, as follows:

SCHEDULE OF INVENTORY

  September 30, 2021  December 31, 2020 
Raw material $56,299  $16,892 
Work in process  -   23,566 
Finished goods  354,382   461,657 
Total inventory $410,681  $502,115 

At September 30, 2021 and December 31, 2020, finished goods included $8,404 and $34,331 on consignment, respectively.

We periodically review the value of our inventory and provide a write-down of inventory based on our assessment of the market conditions. Any write-down is charged to cost of goods sold.

14

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net of accumulated depreciation and amortization, at September 30, 2021 and December 31, 2020 was as follows:

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT, NET

  

September 30, 2021

  December 31, 2020 
Vehicle $41,142  $41,142 
Furniture and equipment  7,494   - 
Extraction equipment  296,747   287,029 
Extraction laboratory  126,707   126,707 
Warehouse facility  50,158   50,158 
Land and land improvement/development  1,501,300   1,456,193 
Accumulated depreciation and amortization  (239,897)  (170,299)
Property, plant and equipment $1,783,651  $1,790,930 

The Company acquired the extraction equipment, laboratory, and warehouse facility during 2018 and 2019 and made preparations and final testing for future production. Final preparations for certain extraction and warehouse work were completed, and these related assets were placed in service on April 1, 2019, at which time we commenced depreciating this asset.

The amount of related depreciation expense for the nine months ended September , 2021 and 2020 is $69,598 and $60,469, respectively.

NOTE 7 – CAPITAL LEASE PAYABLE

Capital lease payable consists of a capital lease agreement entered into in April 2018 to finance the purchase of various lab and manufacturing equipment. The outstanding balance on the 48-month installment capital lease was $148,511 and $161,570 as of September 30, 2021 and December 31, 2020, respectively. The terms of the 48-month capital lease specify monthly payments of $4,575. The interest rate implicit in the lease is about 15% and the maturity date is February 2022.

In addition, the Company entered into additional 48-month leases in May 2019 for production facilities and storage of product. Monthly payments for the facility and storage totals $1,935.

A summary of minimum lease payments on capital lease payable for future years is as follows:

SUMMARY OF MINIMUM LEASE PAYMENTS ON CAPITAL LEASE

  September 30, 2021 
Remainder 2021 $19,530 
2022  32,337 
2023  7,739 
2024  - 
2025  - 
Thereafter  - 
Total minimum lease payments  59,606 
Less: amount representing interest  (2,763)
Capital lease liability $56,843 

15

NOTE 8 – NOTES PAYABLE

During 2015In October 2017, in connection with our purchase of two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and 2016,Ancillary Canna-Business Park, the Company issued promissory notesa first and second trust deed note in the aggregate amountamounts of $942,850 for cash proceeds of $872,500. These$700,000 and $200,000, respectively. The first and second trust deed notes bearare long-term notes and are interest only notes, at 5%-10% per annum13.0%, and several weremature in August 2022, with the principal payment due on various dates throughout 2015at maturity. For the $700,000 loan, the monthly payment is approximately $7,500. For the $200,000 loan, the monthly payment is approximately $2,200. The 1st and 2016 and several are due in 2017. These notes2nd trust deeds are secured by substantially all assetsthe land as well as property owned by two officers of the Company.company and three other related parties. Also, each party has personally guaranteed or pledged additional collateral. The convertible promissory notes are convertible into sharesinclude a debt discount as of the Company’s common stock at a rate equal to $0.01-September 30, 2021 of $0.05 per share, subject to downward adjustments for future equity issuances. 30,600.

In connection with these convertible promissory notes,April 2018, the Company issued warrantsa note due 60 days after funding with a principal amount of $250,000 and interest totaling $125,000. As of September 30, 2021, the note has not been repaid and was amended to purchase 66,500,000 shares of common stock atcarry an exercise price of $0.01 per share, subject to downward adjustments for future equity issuances. The warrants have a term of 7 years from the date of issuance. The Company is in default under the terms of these notes.

The conversion features and warrants are considered derivative liabilities pursuantto ASC815 and were measured at their grant-date fair value and recorded as a liability and note discount on the date of issuance. Subsequent changestothe valueadditional 10% interest rate of the derivative liabilities are recorded in earnings. As a result, during the year ended December 31, 2016,total balance due, Accrued interest for this loan totals $190,625. The note is past due. Two officers of the Company recordedhave personally guaranteed the loan.

In September 2019, the Company issued another note of $102,569 to an initialunrelated party with 5% interest, which was repaid in full on October 20, 2020.

NOTE 9 – CONVERTIBLE NOTES PAYABLE

In August 2020, 9,100,380 shares were issued to settle $80,754 debt of a note discountand accrued interest resulting in a loss of $455,000, with an additional immediate charge to$5,225.

Amortization of note discounts, which is included in interest expense, of $749,809 relatingtothe excess value of the derivative liabilities over the promissory notes. Amortization of the note discount amounted to approximately $290,000$509,817 during the nine months ended September 30, 20172021 and $272,000$423,738 for the nine months ended September 30, 2016.2020.

Grapefruit acquired convertible notes in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) On January 5, 2017May 31, 2019, the Company executed the SPA with Auctus pursuant to the terms of which the Company agreed to sell $4,000,000 of the Notes and issue $6,200,000 of callable warrants (the “Warrants” and, together with the Notes, the “Securities”) to Auctus. Auctus is the Selling Security Holder. In addition, on May 31, 2019, we also entered into a financing arrangementregistration rights agreement with five accredited investorsAuctus (the “Investors”“Registration Rights Agreement”), whereby amendmentswe are obligated tocertain convertible note agreements totaling $662,000 were enacted. The amendments file a registration statement to register the convertible note agreements involved(1)extending the maturity datesresale of the note agreements; and (2) amendingshares underlying the optional conversion provisionsSecurities. On July 25, 2019 (as amended on January 17, 2020), a registration statement was filed to comply with the Registration Rights Agreement .. Pursuant to the SPA, Auctus became obligated to purchase the $4,000,000 of Notes from Grapefruit in four tranches as follows: $600,000 at the original note agreementstonow describe an adjustable conversion price basedSPA closing, which was funded on June 6, 2019; the second tranche of $1,422,750 on the completionday IGNG filed the registration statement, which was funded on August 16, 2019; the third tranche of a qualified$1,030,000 was funded the day the SEC declares the registration statement effective and the fourth tranche of $1 million was funded 90 days after effectiveness. As of December 31, 2020, all tranches of this financing offering. If the cumulativewere completed. The Company has received gross proceeds of such offerings exceed $2.5 million,theconversionprice$4,052,750. The Notes have a two-year term and will be adjusted automaticallytomatchbear interest at 10%.

On April 15, 2021, the offering’scompany renegotiated the debt agreement related to these notes modifying the convertible notes conversion price and conversionfrom a variable rate tocommon shares will occur automatically. If the cumulative gross proceeds of such offerings remain below $2.5 million, the a fixed rate conversion price adjusts to matchof $0.075 per share with an effective date of December 31, 2020. As a result of the offering conversion priceagreement, the Company recorded a noncash expense for the Investors. Should there be an event of default under these amended notes, the Investors will have,inadditiontoall the other rights describedinthat certain Securities Purchaser Agreement, the right, at each Investor’s option, to convert the notes into common shares at $0.01 per share. The Company and certain Investors agreedtoamend its warrant agreements to reduce the number of warrants by 75%to16,625,000. The exercise price remains at $0.01 per share. In consideration of this reduction of the number of warrants, the Company issued to the Investors new convertible promissory notesintotal principal amount of $124,688change in the same form asvalue of derivative instruments of $40,372,883, which was simultaneously offset by a noncash gain of $39,640,477 from the original convertible notes described above as amended. These additional convertible notes accrue interest beginning on January 9, 2017 and are due May 18, 2018.

The amendment to the notes and warrants were accounted for as an extinguishment of debt, which resultedresulting a net loss of $753,699 from the renegotiation of the debt.

On February 26, 2021, the company issued a $450,000 convertible to Auctus bearing 12% interest and 1-year maturity date. Principal payments shall be made in a gain on extinguishment of debt totaling $3,668,776 for the nine months ended September 30, 2017. The outstanding derivative liability relating to the amended notes and warrants was approximately $86,930 as of September 30, 2017.

The Investors agreed to lend the Company up to $200,000, in increments of $50,000, at the Company’s discretion (the “Additional Loans”), as long as the Original Notes are not in default. These loans will be evidenced by note agreementssix (6) installments each in the formamount of $75,000 commencing one hundred and eighty (180) days following the original notes as amended, described above, with a maturity dateIssue Date and continuing thereafter each thirty (30) days for six (6) months. Notwithstanding the forgoing, the final payment of May 18, 2018Principal and bear interest at 10% per annum. These notes have a face value of 118.75% of the funds actually advanced and contain conversion features (conversion price of $0.025 per share) making them derivative instruments. As of September 30, 2017, $150,034 of cash proceeds have been received from this agreement, for a total principal outstanding of $178,166. The Additional Loans are secured by a UCC filingInterest shall be due on the Company’s assets. In connection with these note agreements, the derivative liability created by these note agreements and warrants totaled $288,057.Maturity Date. The derivative liability in excess of the cash proceeds received was recorded as a charge to interest expense, which totaled $136,835. conversion price set at $0.075.

In addition, the Company issued 3,750,000 warrantshas eleven other convertible notes comprising $296,000 outstanding and they are currently in the form of the original Warrants as amended granting the Investor the right to purchase, at $0.01 per share in connection with these notes.

default. The outstanding derivative liability relating to the Additional Loans and the related warrants is $23,173 as of September 30, 2017.

The agreement to amend the notes and warrants and to loan additional monies to the Company, as described above, was dependent on the two officers of the Company—Chief Executive Officer Dane Medley and Chief Financial Officer Xavier Aguilera—agreeing to restate their respective employment agreement, which they both have done.

On January 10, 2017, certain note holders converted notes to common shares. The total principal and accrued interest balance converted amounted to $196,797. The conversion resulted in the issuance of 8,627,500 common shares. The fair market value of the common shares on the date of conversion totaled $431,375.

On May 25, 2017 the Company completed the sale of $500,000 of Convertible Promissory Notes (the “Notes“) to two accredited investors (the “Investors”) that are due May 23, 2018 (the “Maturity Date”). After transaction costs, the company netted $425,000 from the sale of the Notes.

These Notes bear interest at the rate of 12% per annum to the Maturity Date and may be redeemed by the Company for 125% of face value within 90 days of issuance and at 135% of face value from 91 days after issuance and before 180 days after issuance. Any amount of principal or interest on these notes which is not paid when due shall bear interest at the rate of 24% per annumvaries from the due date thereof until the same is paid. 5-10%.

If the Notes are not repaid by the end of this period, any balance due is convertible—at the option of the note holders—into common stock at 60% of the lowest closing price for the prior 20 trading days.

In connection with the sale of the Notes, the Investors received a commitment fee totaling 18 million shares valued at $180,000, and the holders of a majority of the principal amount of the Company’s notes outstanding at May 18, 2017 (the “Prior Notes”) executed, as of that date, an Omnibus Amendment that enabled the transaction by (i) extending the maturity date of these Prior Notes to May 18, 2018 and (ii) restricting the rights of all the holders of the Prior Notes, including their right to convert until certain conditions are met. In addition, the holders of these Prior Notes were relieved of their obligation to provide the final note tranche of $50,000.

6. STOCKHOLDERS’ EQUITY Preferred Stock

Upon confirmation of the Company’s Chapter 11 Reorganization Plan, the Company is authorized to issue 2,000 shares of preferred stock, no par value. The rights, privileges, and preferences of the preferred stock are to be determined by the Company’s board of directors and may be issuedinseries.Asof January 18, 2016, Imaging3 issued 2,000 preferred voting sharestoDane Medley, CEO/Chairman. Each share constitutes 350,000 voting shares. The estimated value of these shares was not significant. However, Dane Medley relinquished these voting shares during the first quarter ended March 31, 2017 for consideration of $60,000, which has not yet been paid.

Common Stock

The Company is authorized to issue 1,000,000,000 shares of no par value common stock.

During the nine months ended September 30, 2016, the company issued2021, a total of 4,364,000 $996,620 of convertible notes had been converted to common stock. It comprised of $832,750 of principal and $163,120 of accrued interest and $750 of fees for a total of 13,352,264 shares of common stockstock.

16

NOTE 10 – NOTES PAYABLE, RELATED PARTY NOTES PAYABLES, AND OPERATING LEASE – RELATED PARTY

Notes payable to officers and directors as of September 30, 2021 and December 31, 2020 are due on demand and consisted of the following:

SCHEDULE OF NOTES PAYABLE TO OFFICERS AND DIRECTORS

  September 30, 2021  December 31, 2020 
Payable to an officer and director $335,780  $82,056 
Payable to an individual affiliate of an officer and director  -   40,000 
Payable to a company affiliate to an officer and director  85,092   366,377 
  $420,872  $488,433 

Notes payables bear interest at 10%.

A related party leased two eco-pods in April 2019 and May 2019, which are refurbished shipping containers, located on this specific parcel within Coachillin’. The lease is treated as an operating lease and payment responsibility is ultimately the responsibility of the related party. The Company assumed these lease payment obligations in May 2019. The monthly payments are $1,055 and $880, for cash proceedsthe duration of $159,900the lease terms of four and 32,000,000five years, respectively.

On May 17, 2021, related parties converted $699,236 of principal and accrued interest for a total of 11,710,465 shares of common stock.

NOTE 11 – EQUITY

Preferred Stock

The Company has authorized 1,000,000 shares of $0.0001 par value preferred stock. As of September 30, 2021, and December 31, 2020, there are 0 shares of preferred stock for services, valued at $1,612,500.outstanding.

Common Stock

The Company is authorized to issue 1,000,000,000 shares of $0.0001 par value common stock.

During the nine months ended September 30, 20172021 the Company issued a total of 150,0007,449,937 shares of common stock for cash in the amount of $7,000 and 50,830,000 shares were issued for services rendered valued at $648,300.$303,545; 20,114,651 shares were issued related to legal settlement and debt settlement with related parties valued at $2,281,695; 13,352,264 shares were issued related to the conversion of convertible notes valued at $996,620; 1,000,000 shares were issued for a stock purchase valued at $0.075 per share; 2,000,000 shares were issued for warrant exercised at $0.125 per share; and 4,545,455 shares were issued for the Summit Boys acquisition (Note – 14 Investments) valued at $250,000.

As of October 19, 2017,September 30, 2021, there were approximately 8,375613 record holders of our common stock, not including shares held in “street name” in brokerage accounts the number of which is unknown. As of September 30, 2017,2021, there were 309,313,065554,162,744 shares of our common stock outstanding on record.

Stock Option Plan

During 2014, the Board of Directors adopted, and the shareholders approved, the 2014 Stock Option Plan under which a total of 27,000,0001,811,401 shares of common stock had been reserved for issuance. The 2014 Stock Option Plan will terminate in September 2024.2024.

Stock Options

As of September 30, 2017,2021, employees of the Company hold options to purchase 5,000,000250,000 shares of common stock granted in 2016 at an exercise price of $1.00. On March 28, 2021, the Company granted a board member an option to purchase 750,000 shares of common stock at an exercise price$0.025. There are six month vesting periods for a block of250,000 shares starting October 1, 2021.

$0.025. On September 15,2017, two officers exercised their 8,000,000 options at a cost of $200,000, by offsetting and reducing their deferred salary and other amounts owed to them by the Company.

17

 

     Weighted-
Average
  Weighted-
Average
Remaining
 
Transactions in FY 2017 Quantity  Exercise Price
Per Share
  Contractual
Life
 
Outstanding, December 31, 2016  13,000,000  $0.025   8.61 
Granted  0         
Exercised  (8,000,000)        
Cancelled/Forfeited  0         
Outstanding ,September 30, 2017  5,000,000  $0.025   8.00 
Exercisable, September 30, 2017  5,000,000  $0.025   8.00 

SCHEDULE OF STOCK OPTIONS ACTIVITY

Transactions in FY 2021 Quantity  

Weighted-

Average

Exercise Price

Per Share

  

Weighted-

Average

Remaining

Contractual Life

 
Outstanding, December 31, 2020  250,000  $1.00   3.82 
Granted  750,000   0.025   5.51 
Exercised  -         
Cancelled/Forfeited  -         
Outstanding, September 30, 2021  1,000,000  $0.25   5.08 
Exercisable, September 30, 2021  250,000  $1.00   3.82 

The weighted average remaining contractual life of options outstanding issued under the Planagreements was 8.005.08 years at September 30, 2017.2021.

In April 2017, the Company cancelled 28 million shares of common stock held by officers.NOTE 12 — WARRANTS

7. WARRANTS

Following is a summary of warrants outstanding at September 30, 2017:2021:

SUMMARY OF WARRANTS OUTSTANDING 

Number of      
Warrants  Exercise Price  Expiration Date
 10,827,224  $0.000001  July 2023
 500,000  $0.01  April 2022
 6,250,000  $0.01  August 2022
 5,750,000  $0.01  April 2023
 2,500,000  $0.01  May 2023
 1,625,000  $0.01  August 2023
 56,000,000  $0.02  May 2022
 3,750,000  $0.01  January 2024
Number of Warrants  Exercise Price  Expiration Date
 37,500   0.10  Apr-22
 2,800,000   0.40  May-22
 500,000   0.10  Aug-22
 575,000   0.10  Apr-23
 125,000   0.10  May-23
 162,500   0.10  Aug-23
 302,776   0.10  Jan-24
 14,000,000   0.125  May-24
 15,000,000   0.15  May-24
 8,000,000   0.25  May-24
 20,000,000   0.075  Apr-26
 2,250,000   0.20  Feb-26

Effective May 1, 2017, the BoardGrapefruit recorded warrants to issue common stock upon exercise in its acquisition of DirectorsImaging3, Inc. on July 10, 2019. (See Note 15.) As part of the SEA, the Company authorized the issuance of 56,000,000also issued 16,000,000 warrants to purchase 56,000,00016,000,000 shares of the Company’s common stock at an exercise price of $0.02$0.125 per share, 15,000,000 warrants to purchase 15,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, 8,000,000 warrants to purchase 8,000,000 shares of the Company’s common stock at an exercise price of $0.25 per share for a period of five yearstwo year from the date of issuanceissuance.

In addition to the officersNotes in connection with the SPA agreement, GPFT issued to the Investor a warrant to purchase 16,000,000 shares of its common stock at $0.125 per share, a warrant to purchase 15,000,000 shares at $0.15 per share and a warrant to purchase 8,000,000 shares at $0.25 per share (collectively, the “Warrants”). The Warrants are “cash only” and are callable if GPFT stock trades on the OTCQB at 200% or more of the Company. Thesegiven exercise price for 5 consecutive days.

On February 26, 2021, 2,250,000 warrants were fully-vested upon grant andissue with an exercise price of $0.125 in relation to the convertible note (See Note 9 Convertible note payable). On April 15, 2021 as such, an expense was recognized upon grant. The fair valuepart of the renegotiated terms of the convertible notes, 20,000,000 additional warrants was calculated using a Black-Scholes model and was estimated to be $194,956. The significant assumptions used in the calculations were as follows:issued at an exercise price of $0.075.

18

 

Term5.0 years
Dividend Yield0%
Risk-free rate1.84%
Volatility60%

8.

NOTE 13 — DERIVATIVE LIABILITIES

Grapefruit recorded derivative instruments in its acquisition of Imaging3, Inc. on July 10, 2019. (See Note 15.) The Company’s only asset or liability measured at fair value on a recurring basis was its derivative liability associated with related warrants to purchase common stock and the conversion featurefeatures embedded in convertible promissory notes.

In connection with previous financing transactions, the Company issued warrantstopurchase common stock and convertible promissory notes. These instruments included provisions that could result in a reduced exercise price based on specified full-ratchet anti-dilution provisions. The “reset” provisions were triggered in the event the Company subsequently issued common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than contractually specified amounts. Upon triggering the “reset” provisions, the exercise / conversion price of the instrument will be reduced. Accordingly, pursuantto ASC815, these instruments were not consideredtobe solely indexed totheCompany’s own stock and were not afforded equity treatment.

On April 15, 2021, the company renegotiated conversion terms on $4,502,750 of convertible notes with Auctus. All variable conversion prices were replaced with a fixed conversion price of $0.075. In addition, the Company issued an additional 20,000,000 warrants with an exercise price of $0.075 per share.

The following table summarizes activity in the Company’s derivative liability during the nine monthsnine-month period ended September 30, 2017:2021:

SUMMARY OF DERIVATIVE LIABILITY 

12-31-2016 Balance $5,532,898 
Creation $416,205 
Reclassification to equity $(163,674)
Change in Value and Extinguishment of Debt $(5,674,923)
09-30-2017 Balance $110,506 
12-31-20 Balance $118,641 
12-31-20 Balance $118,641 
Creation/acquisition  - 
Reclassification of equity  - 
Change in Value  (91,210)
6-30-21 Balance $27,431 

The Company classifies the fair value of these derivative liabilities under level 3 of the fair value hierarchy of financial instruments. The fair value of the derivative liability was calculated using a Black-ScholesBinomial Tree model. The Company’s stock price and estimates of volatility are the most sensitive inputs in validation of assets and liabilities at fair value. The liabilities were measured using the following assumptions:

SCHEDULE OF ASSUMPTIONS USED

Term0.51-3 years - 7.0 years
Dividend Yield0%
Risk-free rate1.20%0.07% - 1.77%0.16%
Volatility60167%

9.

NOTE 14 – INVESTMENTS

Investment in Hemp

In September 2019, the Company invested in hemp product that was purchased and stored by a third party. The Company expects to sell the product by the beginning of next year. Due to the increased harvests, the salability of the product decreased, necessitating the markdown during this quarter.

19

NOTE 15 – COMMITMENTS AND CONTINGENCIES

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLPAlpha Capital Anstalt and Brio Capital Master Fund, LTD

On January 30, 2017 the Company entered into a new Agreement. Under the terms of the Agreement, the Company has agreed to pay Greenberg $1,117,574 plus any interest that has accrued at the rate of 6.0% per annum, as follows: (i) $100,000 on or before December 31, 2017; (ii) $150,000 on or before December 31, 2018 (iii) 4.0% of the first $2.5 million of gross proceeds of any private or public offering by the company (an “Offering”); (iv) 2.0% of the next $2.5 million of gross proceeds from such Offerings; (v) 4.0% of any gross proceeds thereafter from such Offerings; and (vi) the remaining balance on or before December 31, 2019.

In addition, Greenberg has the option to convert up to $150,000 of the balance into a warrant that would convert on terms that are equal to (or, in certain cases, better than) the terms offered in subsequent rounds of financing.

Bankruptcy Closure

On January 31, 2017, United States Bankruptcy Judge for the Central District of California, Neil Bason, granted the company’s unopposed motion for entry of final decree and also granted approval of the two stipulations regarding payment of court-approved fees. The Company noted that as a result, the Imaging3 Chapter 11 proceeding is now closed—the company is no longer subject to the jurisdiction of the Bankruptcy Court, and the case cannot be converted to a Chapter 7 proceeding.

Toclarify, the Judge’s orderinits final paragraph stated that “Notwithstanding the foregoing [order closingthebankruptcy case pursuant to 11United States Code Section 350(a)] the bankruptcy case may be reopened on motionasset forth in the Greenberg, Glusker Fee Agreement and/or the Mentor Fee Agreement and thus the court retains jurisdiction for those purposes and as otherwise provided by law or as contemplated by the prior orders and proceedings of this court”. Thusly, technically, the case could possibly be reopened by either of those aforementioned creditors.

Pending Litigation

On September 13, 2017, Alpha Capital Anstalt and Brio Capital Master Fund, LTD, two minority members of a group of investors in the Company (the “Plaintiff”) filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. TheOn November 21, 2017, the Court denied the Plaintiff’s request for injunctive relief against the Company. As a result, the case essentially became an action for money damages against the Company, believeswhich the lawsuit isCompany believed to be without merit and is aggressively defending against it. The litigation is currently in its preliminary pleading stage anddefended vigorously. However, on July 27, 2018 United States District Court for the Southern District of New York granted the plaintiffs motion for summary judgement, awarding them approximately $1.4 million dollars. On April 15, 2019 the Company is seekingexecuted a settlement agreement (the “Settlement Agreement”) with the defendants to havesettle the injunctive countsmatter by agreeing to pay the defendants an aggregate of $200,000 and issuing them an aggregate of 7,705,698 of the lawsuit dismissedCompany’s common shares (subject to certain possible adjustments to the amount of shares to be issued to the Defendants by the Company). The Company paid this $200,000 to the defendants and issued the 7,705,698 shares to the defendants in the fourth quarter of 2019. Subsequently, the defendant’s claimed the aforementioned share adjustment had been triggered and made a demand that the Company issue additional shares pursuant to the terms of the Settlement. In April 2021, the Company issued an additional aggregate of 2,822,654 shares the Company’s stock to these defendants in final settlement of the dispute.

Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP vs Imaging3, Inc. Settlement

The Company came to a settlement with Galileo Surgery Center LP/Cypress Ambulatory Surgery Center LP (“Galileo”) for failure$75,572 with an interest rate of 10%, requiring payments of $7,300 per month beginning in August 2021 until paid in full.

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLP

The Company came to state a causesettlement agreement with Greenberg Glusker Fields Claman & Machtinger LLP (“Greenberg”). Three $68,000 payments are to be made in relation to the timing of action.the three latter tranches mentioned in “Auctus Financing” or before November 30, 2019. As of now, $68,000 has been paid; late penalties are currently being assessed. In addition, 7,628,567 shares are to be issued as part of the settlement agreement—7,213,933 of the shares were issued as of September 30, 2020. In May 2021, the Company issued 3,920,865 shares as part of the make-whole clause in the agreement. On October 26, 2021, the Company issued 600,000 shares as part of the make-whole clause in the agreement. Additional shares may need to be issued in the future.

NOTE 16 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10Q and determined that there have been no events that have occurred that would require adjustments to our disclosures in the financial statements.

20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Statements

This Form 10-Q may containcontains financial projections and other “forward-looking statements,” as that term is used in federal securities laws, about Imaging3, Inc.’sGrapefruit’s financial condition, results of operations and business. These statements include, among others:others, statements concerning the potential for revenues and expenses and other matters that are not historical facts. These statements may be made expressly in this Form 10-K. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” or similar expressions used in this Form 10-K. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied by us in those statements. The most important facts that could prevent us from achieving our stated goals include, but are not limited to, the following:

statements concerning the potential benefits that Imaging3, Inc. (“Imaging3” or the “Company”) may experience from its business activities and certain transactions it contemplates or has completed; and
(a)
statements of Imaging3’s expectations, beliefs, future plans and strategies, anticipated developments and other matters that are not historical facts. These statements may be made expressly in this Form 10-Q. You can find many of these statements by looking for words such as “believes,” “expects,” “anticipates,” “estimates,” “opines,” or similar expressions used in this Form 10-Q. These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause Imaging3’s actual results to be materially different from any future results expressed or implied by Imaging3 in those statements. The most important facts that could prevent Imaging3 from achieving its stated goals include, but are not limited to, the following:

(a)volatility or decline of Imaging3’sour stock price;
(b)potential fluctuation in quarterly results;
(c)our failure of Imaging3 to earn revenues or profits;
(d)inadequate capital to continue or expand itsthe business inabilityand barriers to raiseraising the additional capital or to obtaining the financing needed to implement itsour business plans;
(e)failure to commercialize Imaging3’s technology or to make sales;
(f)changes in demand for Imaging3’sour products and services;
(g)rapid and significant changes in markets;
(h)litigation with or legal claims and allegations by outside parties;parties, causing us to incur substantial losses and expenses;
(i)insufficient revenues to cover operating costs, resulting in persistent losses;costs;
(j)dilution in the ownership of the Company through the issuance by us of additional securities and the conversion of outstanding warrants, notes and other securities; and
(k)failure of Imaging3 to obtain approval of its proprietary medical imaging technology and device from the Federal Food and Drug Administration.

There is no assuranceWe cannot assure that Imaging3we will be profitable. Imaging3We may not be able to successfully develop, manage or market itsour products and services. Imaging3services successfully. We may not be able to attract or retain qualified executives and technology personnel. Imaging3We may not be able to obtain customers for itsour products or services. Imaging3’sOur products and services may become obsolete. Government regulation may hinder Imaging3’sour business. Imaging3 may not be able to obtain the required approvals from the United States Food and Drug Administration for its products and services. Additional dilution in outstanding stock ownership maywill be incurred due to the issuance or exercise of more shares, warrants and stock options, or the exercise of outstanding warrants and stock options, or the conversion of notes. Imaging3 is exposed to other risks inherent in its businesses.convertible securities.

Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by the forward-looking statements. Imaging3 cautionsWe caution you not to place undue reliance on the statements, which speak only as of the date of this Form 10-Q. The cautionary statements contained or referred to in this section should be considered in connection with any subsequent written or oral forward-looking statements that Imaging3we or persons acting on itsour behalf may issue. Imaging3 doesmake. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Current Overview

21

 

Though our efforts have been to market our refurbished equipment, a significant portion of our sales and revenues derive from services and the sale of parts, either from extended warranty purchases at the time of purchase of the refurbished equipment, or service contracts and time and material revenue realized upon warranty expiration, the majority of which is realized one year from equipment purchase as warranties expire.

Our sales effort through direct mail, broadcast facsimile and broadcast email to thousands of potential customers throughout the United States generates leads of potential customers desiring to purchase equipment either immediately orThe following discussion should be read in the course of one year. This lead generation through direct mail, broadcast and email will continue on a quarterly basisconjunction with the goal of increasing the total number of our leads for our sales staff. Management expects that the marketing program will also eventually help stabilize the company.

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements which have been preparedand notes to those statements. In addition to historical information, the following discussion and other parts of this annual report contain forward-looking information that involves risks and uncertainties.

Results of Operations for the Three Months Ended September 30, 2021 as compared to the Three Months Ended September 30, 2020.

  Three months ended  Three months ended 
  September 30, 2021  September 30, 2020 
Net revenues $153,476  $1,306,201 
Cost of goods sold  346,073   1,123,717 
Gross income (loss)  (192,597)  182,484 
Sales expense  3,800   67,479 
Stock based compensation  25,980   - 
Stock option expenses  32,877   - 
General and administrative expense  352,462   289,767 
Loss from operations  (607,716)  (174,762)
Change in value of derivatives  13,877   (7,014,164)
Interest and other income (expense)  (388,273)  (500,768)
Net loss before income taxes  (982,112)  (7,689,694)
Tax provision  -   - 
Net loss  (982,112)  (7,689,694)
Loss attributable to noncontrolling interest  (270)  - 
Net loss attributable to Grapefruit USA, Inc. $(981,842) $(7,689,694)

The following sets forth selected items from our statements of operations for three months ended September 30, 2021 and for the three months ended September 30, 2020.

Revenue for the three months ended September 30, 2021 was $153,476 compared to $1,306,201 for the corresponding period in accordance with accounting principles generally accepted2020, a decrease of $1,152,725 or 88.3%. This decrease in revenue is primarily due to the fact that there was a very strong cannabis crop in the United Stateslast quarter of America.2020, which drove down wholesale cannabis prices significantly and limited the profitability of our distribution and trading operations. The preparationCompany expects such cyclical revenue deviations to be mitigated in 2021 and following years by a significant growth of revenue from our HourGlass products, which will be unaffected by these financial statements requires uscyclical events.

Cost of goods sold for the three months ended September 30, 2021 was $346,073 as compared to make estimates$1,123,717 for the corresponding period in 2020, a decrease of $777,644, or 69.2%. Included in cost of goods sold the three months ended September 30, 2021 and judgments that affect the reported amounts of assets, liabilities, revenues2020 are plant operation and other direct overhead expenses and related disclosure of contingent assets and liabilities. We monitorincurred to maintain our estimates on an on-going basis for changes in facts and circumstances, and material changes in these estimates could occurproduction facilities. Included in the future. Changescost of goods sold is the markdown of the hemp investment of $85,000. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. Consequently, we expect our gross margins to significantly improve in estimates are recorded infuture periods as sales increase.

Our resulting gross loss for the three months ended September 30, 2021 was $192,597 as compared with the gross income of $182,484 for the corresponding period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under2020, a decrease of $375,081, or 205.5%.

22

Sales expense for the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

We have identified the policies below as critical to our business operations and the understanding of our results of operations.

Revenue Recognition

Revenue is recognized upon shipment, provided that evidence of an arrangement exists, title and risk of loss have passedthree months ended September 30, 2021 was $3,800 compared to the customer, fees are fixed$67,479 for 2020, a decrease of $63,679. The decrease was a result of all sales being made in-house by management. Stock based compensation for the three months ended September 30, 2021 was $25,980 compared to $0 for 2020, an increase of $25,980. Stock option expenses for the three months ended September 30, 2021 were $32,877 compared to $0 for 2020, an increase of $32,877. General and administrative expenses for the three months ended September 30, 2021 were $352,462 compared to $289,767 for 2020, an increase of $62,695, or determinable and collection21.6%.

Our resulting net loss from operations for the three months ended September 30, 2021 was $607,716 as compared to $174,762 for the corresponding period for 2020, an increase of $432,954, or 247.7%.

Our resulting net loss attributable to Grapefruit USA, Inc. for the related receivablethree months ended September 30, 2021 was $982,112 as compared to $7,689,694 for the corresponding period for 2020, a decrease of $6,707,582, or 87.2%. The decrease is reasonably assured. Revenue is recorded net of estimated product returns, which is based upon the Company’s return policy, sales agreements, management estimates of potential future product returns related to current period revenue, current economic trends, changes in customer composition and historical experience. The Company accrues for warranty costs, sales returns, and other allowances based on its experience. Generally, the Company extends credit to its customers and does not require collateral. The Company performs ongoing credit evaluations of its customers and historic credit losses have been within management’s expectations and has a revenue receivables policy for service and warranty contracts. Equipment sales usually have a one year warranty of parts and service. After a one year period, the Company contacts the buyer to initiate the sale of a new warranty contract for one year. Warranty revenues are deferred and recognized on a straight-line basis over the term of the contract or as services are performed.

Deferred Revenue

Deferred revenue consists substantially of amounts received from customers in advance of the Company’s performance service period. Deferred revenue is recognized as revenue on a systematic basis that is proportionatedue largely to the period that$7,014,164 non-cash loss from the underlying services are rendered, whichchange in certain arrangements is straight-line overvalue of derivative for the remaining contractual term or estimated customer life of an agreement.quarter ended September 30, 2020.

Research and Development

Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, and overhead directly related to the Company’s research and development operations, as well as costs to acquire technology licenses.

Other Accounting Factors

The effects of inflation have not had a material impact on our operation, nor are they expected to in the immediate future.

Although we are unaware of any major seasonal aspect that would have a material effect on the financial condition or results of operations, the first quarter of each fiscal year is always a financial concern due to slow collections after the holidays.

Results of OperationOperations for the Nine Months Ended September 30, 2017 Compared2021 as compared to the Nine Months Ended September 30, 20162020.

We had revenues in the first

  Nine Months Ended  Nine Months Ended 
  September 30, 2021  September 30, 2020 
Net revenues $586,780  $2,580,412 
Cost of goods sold  926,671   2,385,804 
Gross income (loss)  (339,891)  194,608 
Sales expense  5,760   106,594 
Stock based compensation  265,024   - 
Stock option expenses  65,754   - 
General and administrative expense  1,011,199   974,925 
Loss from operations  (1,687,628)  (886,911)
Change in value of derivatives  91,210   (7,946,046)
Interest and other income (expense)  (2,149,021)  (1,237,279)
Net loss before income taxes  (3,745,439)  (10,070,236)
Tax provision  -   - 
Net loss  (3,745,439)  (10,070,236)
Loss attributable to noncontrolling interest  (270)  - 
Net loss attributable to Grapefruit USA, Inc. $(3,745,169) $(10,070,236)

The following sets forth selected items from our statements of operations for nine months of 2017 of $14,624ended September 30, 2021 and for the nine months ended September 30, 2020.

Revenue for the nine months ended September 30, 2021 was $586,780 compared to $40,393$2,580,412 for the corresponding period in 2016. The2020, a decrease of $1,993,632 or 77.3%. This decrease in revenue is primarily due to decreased warranty sales.

Our costthe fact that there was a very strong cannabis crop in the last quarter of 2020, which drove down wholesale cannabis prices significantly and limited the profitability of our distribution and trading operations. The Company expects such cyclical revenue deviations to be mitigated in 2021 and following years by a significant growth of revenue was $14,263 infrom our HourGlass products, which will be unaffected by these cyclical events.

Cost of goods sold for the first nine months of 2017ended September 30, 2021 was $926,671 as compared to $10,247$2,385,804 for the corresponding period in 2016. The increase2020, a decrease of $1,459,133, or 61.2%. Included in cost of revenuegoods sold the nine months ended September 30, 2021 and 2020 are plant operation and other direct overhead expenses incurred to maintain our production facilities. These fixed carrying costs affect our gross margin more significantly at lower revenues than at our anticipated full operating activity levels. Consequently, we expect our gross margins to significantly improve in future periods as sales increase.

23

Our resulting gross loss for the nine months ended September 30, 2021 was $339,891 as compared with the gross income of $194,608 for the corresponding period in 2020, a decrease of $534,499.

Sales expense for the three months ended September 30, 2021 were $5,760 compared to the $106,594 for 2020, a decrease of $100,834, or 94.6%. The decrease was a result of outside labor costs relatedthe majority sales being made in-house by management. Stock based compensation for the nine months ended September 30, 2021 were $265,024 compared to C-Arm repairs $0 for 2020, an increase of $265,024. Stock option expenses for the nine months ended September 30, 2021 were $65,754 compared to $0 for 2020, an increase of $65,754. General and administrative expenses for the nine months ended September 30, 2021 were $1,011,199 compared to $974,925 for 2020, an increase of $36,274, or 3.7%. We had a gross profit

Our resulting net loss from operations for the nine months ended September 30, 2021 was $1,687,628 as compared to $886,911 for the corresponding period for 2020, an increase of $800,717, or 90.3%.

As part of the reverse merger in July 2019, the Company recorded derivative liabilities substantially in the firstform of convertible notes and related warrants with variable conversion features. On April 15, 2021, the company renegotiated the debt agreement with the lender modifying the convertible notes conversion price from a variable rate to a fixed rate conversion price for $4,502,750 of convertible notes, with an effective date of December 31, 2020. The change in value of derivatives, a non-cash gain, for the nine months of 2017 of $361ended September 30, 2021, was $91,210 as compared to a gross profitnon-cash expense of $30,146$7,946,046 for the corresponding period for 2020.

Included in interest and other expense for the same period of 2016. Again, lack of sales had a direct impact on decreased gross profit margin. Our operating expenses decreased to $1,507,048 in the first nine months ended September 30, 2021 is a non-cash expense of 2017$513,267 related to shares issued as part of a make-whole agreement (see Note 15 Commitments and contingencies) and $491,998 loss on extinguishment of debt for related parties.

Our resulting net loss attributable to Grapefruit USA, Inc. for the nine months ended September 30, 2021 was $3,745,169 as compared to $10,070,236 for the corresponding period for 2020, a decrease of $6,325,067, or 62.8%.

Development of hi-tech cultivation facility.

During 2018 we reviewed various facilities and identified a suitable, compliant cannabis facility located in the city of Dessert Hot Springs, to build our manufacturing and distribution facility. This commercial park is owned and operated by Coachillin’ Holding LLC and we purchased land rights from Coachillin’ Holding LLC on December 21, 2017 to secure our specific location within their commercial park. As a result, we own approximately two acres of real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Rd., approximately 10 miles north of the center of Palm Springs.

Grapefruit intends to build out its real property into a distribution, manufacturing and high-tech cultivation facility in two phases to further its goal to become a seed to sale, fully vertically integrated Cannabis and CBD product Company. Grapefruit’s plans include an indoor 40,000 square foot multi-tiered canopy and adjoining tissue culture rooms divided into two separate buildings on our Coachillin property. The development of the lot will take place in two phases.

On July 29, 2021, Grapefruit obtained its development permit to construct phase one. Phase one will be comprised of a 30,000 square foot facility containing a 10,000 square foot state-of-the-art indoor canopy, a separately licensed Distribution facility and Manufacturing lab that will carry a Type 7 volatile manufacturing license. The canopy is estimated to produce thousands of pounds of the highest quality indoor cultivars of cannabis annually. We are in the process of securing construction financing for Phase one.

In order for us to obtain California cannabis licensing from state and local officials we entered into an operating costslease with Coachillin’ Holdings to temporarily occupy an area near the location of $2,051,898our permanent location within the Coachillin’ commercial park.

24

COVID-19 Impact

During the nine months ended September 30, 2021, the company experienced severe restrictions on consumers and the retail locations at which consumers purchase our products. As a result of these restrictions, we believe demand for our products was subdued during the period. During the comparable nine months in 2016, primarily2020, and as a result of stock based compensation activity. The loss from operations was $1,506,687the COVID-19 pandemic, we saw an increase in demand for our cannabis products driven by consumer pantry-loading and increased consumption of our products due to concerns about future availability of products and or concerns about whether retail locations that sell our products would remain open. Despite the COVID-19 pandemic, we have been able to keep up with fluctuating consumer demand for our products and have continued to introduce new products in the firstmarket.

The full extent to which COVID-19 may impact our business, including our operations and the market for our securities and our financial condition, will depend on future developments, which are highly uncertain and cannot be predicted at this time. These include the duration, severity and scope of the pandemic, the development and availability of effective treatments and vaccines, and further action taken by the government and other third parties in response to the pandemic. In particular, COVID-19 and government efforts to curtail COVID-19 could impede our production facilities, increase operating expenses, result in loss of sales, affect our supply chains, impact performance of contractual obligations and require additional expenditures to be incurred.

Liquidity and Capital Resources

Our cash position decreased to $37,317 as of September 30, 2021 from $299,895 as of December 31, 2020. Our total current assets decreased to $847,939 as of September 30, 2021, from $948,862 as of December 31, 2020.

Our total current liabilities increased to $4,786,109 as of September 30, 2021 from $4,379,581 as of December 31, 2020.

During the nine months of 2017 compared to a loss of $2,021,752 in 2016. Our net income was $3,341,377 in the first nine months of 2017 compared to a net loss of $6,116,611 in the first nine months of 2016, as a result of a derivative liability activity and gains on the extinguishment of debt.

Results of Operation for the Three Months Endedended September 30, 2017 Compared to the Three Months Ended September 30, 2016

We had revenues in the third quarter2021, we used $998,581 of 2017 of $4,946 compared to $23,195 in 2016. The decrease in revenue is due to decreased warranty sales.

Our cost of revenue was $221 in the third quarter of 2017 compared to $1,905 in 2016. The decrease in cost of revenue was a result of diminished salesnet cash for the period. We had a gross profit in the third quarter of 2017 of $4,725 compared to a gross profit of $21,290 in the same period of 2016. Again, lack of sales had a direct impact on decreased gross profit margin. Our operating expenses increased to $652,178 in the third quarter of 2017activities, as compared to $417,845 in 2016, mainly due to stock based compensation activity in 2017. We had a loss fromcash used by operations of $647,453 in the third quarter of 2017 compared to a loss of $396,555 in 2016. Our net loss was $667,634 in the third quarter of 2017 compared to a net loss of $974,100 in the third quarter of 2016, as a result of derivative liability activity and stock based compensation$910,335 used during the 2016 period.

Liquidity and Capital Resources

The Company’s cash position was $26,079 atnine months ended September 30, 2017, compared to $22,638 at December 31, 2016. The increase in September was due to proceeds received from the issuance of a new note payable.

As of September 30, 2017, the Company has a working capital deficit of $2,192,228 as compared to $8,148,197 at December 31, 2016. This disparity was due primarily to a new agreement entered into with Greenberg Glusker Fields Claman & Machtinger LLP. (See Part II Other Information below for details), the settlement of debt in January 2017 and the resulting effect of the gain on extinguishment of debt.

2020. Net cash used in operatinginvesting activities amounted to $578,594 forduring the nine month periodmonths ended September 30, 2017,2021 was $62,319, as compared to net cash used in operating activities of $394,697 for$25,469 during the nine month periodmonths ended September 30, 2016 due primarily to the settlement of debt in January 2017 and the resulting effect of the gain on the extinguishment of debt.

2020. Net cash provided by financing activities amounted to $582,035 and $454,900 forduring the nine month periodsmonths ended September 30, 2017 and 2016, respectively. The increase in 20172021 was $798,253, as compared to 2016 resulted mainly from an increase$835,040 during the nine months ended September 30, 2020.

During the nine months ended September 30, 2021, the Company converted $966,620 of principal and accrued interest for shares of common stock. We expect to continue to exchange the long-term convertible notes to equity in the future.

We expect our working capital requirements in the next year to be met primarily by the proceeds from theof issuance of notes payable duringdebt, equity and other securities to our existing creditors, shareholders, and other investors, as well as from cash flow from operations. We also expect that, as in the period.

The Company does not have sufficient capitalpast, significant amounts of our convertible debt with a major lender will be converted into equity. We expect to meet its current cash needs, which include the costs of compliance with the continuing reporting requirements of the Securities Exchange Act of 1934, as amended. The Company intends to seekneed additional capital and long term debt financing to attempt to overcome its working capital deficit. The Company will need between $50,000 and $100,000 annuallyfrom outside sources to maintain its reporting obligations. The Company may attempt to do more private placements of its stock in the future to raise capital, but therecover our anticipated operating expenses. There is no assurance that the Company canwill be able to raise sufficient additional capital or obtain sufficient financing to enable itcontinue in business or to obtain approvaleffectively execute its business plan.

Going Concern Qualification

Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of its prototype frombusiness for the Federal Food and Drug Administration and to sustain monthly operations. In order to address itsforeseeable future. During the nine months ended September 30, 2021, we incurred a net loss of $3,745,439, had a working capital deficit the Company also intends to endeavor to (i) reduce operating costs, (ii) reduce general, administrativeof $3,938,170 and selling costs, (iii) increase saleshad an accumulated deficit of its existing products and services, and (iv) obtain the approval of the United States Food and Drug Administration to the Company’s proprietary medical imaging device so that the Company can commence marketing and selling it. There may not be sufficient funds available to the Company to enable it to remain in business and the Company’s needs for additional financing are likely to persist.

Going Concern Qualification

The Company has incurred significant losses from operations, and such losses are expected to continue. The Company’s auditors have included a “Going Concern Qualification” in their report for the years ended December 31, 2016, 2015, 2014, 2013 and 2012. In addition, the Company has limited working capital. The foregoing raises substantial doubt about the Company’s$15,066,663 at September 30, 2021. Our ability to continue as a going concern. Management’s plans include seeking additional capital and/concern is dependent upon our ability to generate profitable operations in the future and, or, debt financing.obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations as they come due. There is no guaranteeassurance that additional capital and/or debt financingthese events will be available when andsatisfactorily completed. As a result, there is doubt about our ability to the extent required, or that if available, it will be on terms acceptable to the Company. The financial statements do not include any adjustments that might resultcontinue as a going concern for one year from the outcomeissuance date of this uncertainty. The “Going Concern Qualification” might make it substantially more difficult to raise capital.these financial statements

Off-Balance Sheet Arrangements

None.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable.

25

 

Not applicable.

Item 4. Controls and Procedures

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934 (the “Exchange Act”)adequate internal control over financial reporting as such term is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures”defined in Rule 15d-15(e)13a-15(f) under the Exchange Act. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how wellInternal control over financial reporting is a process designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

At the end of the period covered by this Quarterly Report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officerprincipal executive and Chief Financial Officer,financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

As of September 30, 2021, our management assessed the effectiveness of our internal control over financial reporting using the design and operationcriteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our disclosure controls and procedures. Based upon the foregoing, our Chief Executive Officer and Chief Financial Officermanagement concluded that, as of September 30 2017, the disclosure controls and procedures of2021, our Company were not effective to ensure that the information required to be disclosed in our Exchange Act reports was recorded, processed, summarized and reported on a timely basis.

Imaging3 is undertaking to improve its internal control over financial reporting and improve its disclosure controls and procedures. As of December 31, 2016 we had identified the following material weaknesses which still exist as of September 30, 2017 andwas effective based on those criteria.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting through the date of this report:

1. As of September 30, 2017, and as of the date of this report we did not maintain effective controls over the control environment. Specifically, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

2. As of September 30, 2017, and as of the date of this report, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

3. As of September 30, 2017, and as of the date of this report, we did not maintain adequate segregation of duties. Accordingly, management has determined that this control deficiently constitutes a material weakness.

Changes in Internal Control Over Financial Reporting

There were no changes in internal controls over financial reporting that occurredor during the quarter ended September 30, 2017,2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This report does not include an attestation report offrom our registered public accounting firm regarding internal control over financial reporting.

PART II. OTHER INFORMATION

Administrative Claim of Greenberg Glusker Fields Claman & Machtinger LLPItem 1. Legal Proceedings

On January 30, 2017 the Company entered into a new Agreement. Under the terms of the Agreement, the Company has agreed to pay Greenberg $1,117,574 plus any interest that has accrued at the rate of 6.0% per annum, as follows: (i) $100,000 on or before December 31, 2017; (ii) $150,000 on or before December 31, 2018 (iii) 4.0% of the first $2.5 million of gross proceeds of any private or public offering by the company (an “Offering”); (iv) 2.0% of the next $2.5 million of gross proceeds from such Offerings; (v) 4.0% of any gross proceeds thereafter from such Offerings;Alpha Capital Anstalt and (vi) the remaining balance on or before December 31, 2019.Brio Capital Master Fund, LTD

In addition, Greenberg has the option to convert up to $150,000 of the balance into a warrant that would convert on terms that are equal to (or, in certain cases, better than) the terms offered in subsequent rounds of financing.

Bankruptcy Closure

On January 31, 2017, United States Bankruptcy Judge for the Central District of California, Neil Bason, granted the company’s unopposed motion for entry of final decree and also granted approval of the two stipulations regarding payment of court-approved fees. The Company noted that as a result, the Imaging3 Chapter 11 proceeding is now closed—the company is no longer subject to the jurisdiction of the Bankruptcy Court, and the case cannot be converted to a Chapter 7 proceeding.

To clarify, the Judge’s order in its final paragraph stated that “Notwithstanding the foregoing [order closing the bankruptcy case pursuant to 11United States Code Section 350(a)] the bankruptcy case may be reopened on motion as set forth in the Greenberg, Glusker Fee Agreement and/or the Mentor Group Fee Agreement and thus the court retains jurisdiction for those purposes and as otherwise provided by law or as contemplated by the prior orders and proceedings of this court”. Thusly, technically, the case could possibly be reopened by either of those aforementioned creditors.

Pending Litigation

On September 13, 2017, Alpha Capital Anstalt and Brio Capital Master Fund, LTD, two minority members of a group of investors in the Company (the “Plaintiff”) filed a lawsuit seeking damages and injunctive relief in the United States District Court for the Southern District of New York claiming that the Company breached certain Note and Warrant agreements among the parties to the action. The holders of the majority of the investment involved in the above lawsuit chose not to join in the lawsuit and have informed the Company that they believe the lawsuit to be baseless. TheOn November 21, 2017, the Court denied the Plaintiff’s request for injunctive relief against the Company. As a result, the case essentially became an action for money damages against the Company, believeswhich the lawsuit isCompany believed to be without merit and is aggressively defending against it. The litigation is currently in its preliminary pleading stage anddefended vigorously. However, on July 27, 2018 United States District Court for the Southern District of New York granted the plaintiffs motion for summary judgement, awarding them approximately $1.4 million dollars. On April 15, 2019 the Company is seekingexecuted a settlement agreement (the “Settlement Agreement”) with the defendants to havesettle the injunctive countsmatter by agreeing to pay the defendants an aggregate of $200,000 and issuing them an aggregate of 7,705,698 of the lawsuit dismissed for failureCompany’s common shares (subject to statecertain possible adjustments to the amount of shares to be issued to the Defendants by the Company). The Company paid this $200,000 to the defendants and issued the 7,705,698 shares to the defendants in the fourth quarter of 2019. Subsequently, the defendant’s claimed the aforementioned share adjustment had been triggered and made a causedemand that the Company issue additional shares pursuant to the terms of action.the Settlement. In April 2021, the Company issued an additional aggregate of 2,822,654 shares the Company’s stock to these defendants in final settlement of the dispute.

Item 1A. Risk Factors

Not applicable because weSmaller reporting companies are a smaller reporting company.not required to provide the information required by this item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the period covered by this quarterly report.

26

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

(a) Exhibits

EXHIBIT NO.DESCRIPTION
31.1Section 302 Certification of Chief Executive Officer
31.2Section 302 Certification of Chief Financial Officer
32.1Section 906 Certification
32.2Section 906 Certification
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

27

 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IMAGING3, INC.
Dated: November 14, 2017By:/s/ Dane Medley
Dane Medley
Chief Executive Officer
and Chairman (Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

/s/ Dane MedleyBradley J. YouristDated: November 14, 201722, 2021
Dane Medley, Bradley J. Yourist
Chief Executive Officer
and Chairman (Principal Executive Officer)
/s/ Kenneth J. BiehlDated: November 22, 2021
/s/ Xavier AguileraKenneth J. BiehlDated: November 14, 2017

Xavier Aguilera, Chief Financial Officer
Secretary, and Executive Vice President
(Principal Financial/Accounting Officer)

28